Durham.

PositionTriangle

DURHAM--Drug developer Tranzyme netted about $48 million in its initial public offering of stock, despite having to cut the price of its shares. It originally sought to sell 5 million at $11 to $13 each, but...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT